Oral sodium thiosulfate as maintenance therapy for calcific uremic arteriolopathy: A case series

American Journal of Nephrology

Volumn 37, Issue 2, 2013, Pages 104-109

  Albugami, Meteb M ^a   Wilson, Jo Anne ^a   Clarke, James R ^b   Soroka, Steven D ^a  

^a Division of Nephrology   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Calciphylaxis; Maintenance therapy; Sodium thiosulfate

Indexed keywords

SODIUM THIOSULFATE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CALCIFIC UREMIC ARTERIOLOPATHY; CALCINOSIS; CASE STUDY; COHORT ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG TOLERABILITY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOLOGIST; TREATMENT DURATION;

EID: 84873048921     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000346410     Document Type: Article

References (28)

1. Angelis M, Wong LL, Myers SA, Wong LM: Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 1997; 122: 1083-1090.
2. Rogers NM, Coates PTH: Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens 2008; 17: 629-634.
3. Klassen G: Calcified subcutaneous arterioles with infarcts of the subcutis and skin ('calciphylaxis') in chronic renal failure. Am J Kidney Dis 2000; 35: 588-597.
4. Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO: Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001; 60: 324-332.
5. Coates T, Kirkland GS, Dymock RB, Murphy BF, Brealey JK, Mathew TH, Disney AP: Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 1998; 32: 384-391.
6. Fine A, Zacharias J: Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002; 61: 2210-2217.
7. Fine A, Zacharias J: Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002; 61: 2210-2217.
8. Araya CE, Fennell RS, Neiberger RE, Dharnidharka VR: Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults. Clin J Am Soc Nephrol 2006; 1: 1161-1166.
9. Roe SM, Graham LD, Brock WB, Barker DE: Calciphylaxis: early recognition and management. Am Surg 1994; 60: 81-86.
10. Russell R, Brookshire MA, Zekonis M, Moe SM: Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca × P product and aggressive wound care. Clin Nephrol 2002; 58: 238-243.
11. Girotto JA, Harmon JW, Ratner LE, Nicol TL, Wong L, Chen H: Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery 2001; 130: 645-651.
12. Robinson MR: Cinacalcet for the treatment of calciphylaxis. Arch Dermatol 2007; 143: 152-154.
13. Monney P, Nguyen QV, Perroud H, Descombes E: Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant 2004; 19: 2130-2132.
14. Basile C, Montanaro A, Masi M, Pati G, De Maio P, Gismondi A: Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series. J Nephrol 2002; 15: 676-680.
15. Cicone JS, Petronis JB, Embert CD, Spector DA: Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004; 43: 1104-1108.
16. Brucculeri M, Cheigh J, Bauer G, Serur D: Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. Semi Dial 2005; 18: 431-434.
17. Baldwin C, Farah M, Leung M, Taylor P, Werb R, Kiaii M, Levin A: Multi-intervention management of calciphylaxis: a report of 7 cases. Am J Kidney Dis 2011; 58: 988-991.
18. Musso CG, Enz P, Vidal F, Gelman R, Giuseppe LD, Bevione P, Garfi L, Galimberti R, Algranati L: Oral sodium thiosulfate solution as a secondary preventive treatment for calciphylaxis in dialysis patients. Saudi J Kidney Dis Transpl 2008; 19: 820-821.
19. Yatzidis H, Agroyannis B: Sodium thiosulfate treatment of soft tissue calcifications in patients with end stage renal disease. Perit Dial Int 1987; 7: 250-252.
20. Yatzidis H: Successful sodium thiosulphate treatment for recurrent calcium urolithiasis. Clin Nephrol 1985; 23: 63-67.
21. Agroyannis BJ, Koutsikos DK, Tzanatos HA, Konstadinidou IK: Sodium thiosulfate in the treatment of renal tubular acidosis I with nephrocalcinosis. Scand J Urol Nephrol 1994; 28: 107-108.
22. Agroyannis B: Does long-term administration of sodium thiosulphate inhibit progression to renal failure in nephrocalcinosis? Nephrol Dial Transplant 2001; 16: 2443-2444.
23. Asplin JR, Donahue SE, Lindeman C, Michalenka A, Strutz KL, Bushinsky DA: Thiosulfate reduces calcium phosphate nephrolithiasis. J Am Soc Nephrol 2009; 20: 1246-1253.
24. Miller MH, Toops TC: Acute cyanide poisoning; recovery with sodium thiosulfate therapy. J Indiana State Med Assoc 1951; 44: 1164.
25. Hayden MR, Goldsmith DJA: Sodium thiosulfate: new hope for the treatment of calciphylaxis. Semin Dial 2010; 23: 258-262.
26. Farese S, Stauffer E, Kalicki R, Hildebrandt T, Frey BM, Frey FJ, Uehlinger DE, Pasch A: Sodium thiosulfate pharmacokinetics in hemodialysis patients and healthy volunteers. Clin J Am Soc Nephrol 2011; 6: 1447-1455.
27. Steinijans VW, Sauter R, Jonkman JH, Schulz HU, Stricker H, Blume H: Bioequivalence studies: single vs. multiple dose. Int J Clin Pharmacol Therap Toxicol 1989; 27: 261-266.
28. Mastan S, Latha TB, Ajay S: The basic regulatory considerations and prospects for conducting bioavailability/bioequivalence (BA/ BE) studies-an overview. Comparative Effectiveness Res 2011; 1: 1-25.